Litcius/Paper detail

Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B

Heejoon Jang, Jun Sik Yoon, Soo Young Park, Han Ah Lee, Myoung‐jin Jang, Seung Up Kim, Dong Hyun Sinn, Yeon Seok Seo, Hwi Young Kim, Sung Eun Kim, Dae Won Jun, Eileen L. Yoon, Joo Hyun Sohn, Sang Bong Ahn, Jae‐Jun Shim, Soung Won Jeong, Yong Kyun Cho, Hyoung Su Kim, Joon Yeul Nam, Yun Bin Lee, Yoon Jun Kim, Jung‐Hwan Yoon, Fabien Zoulim, Pietro Lampertico, George Ν. Dalekos, Ramazan Idılman, Vana Sypsa, Thomas Berg, Marı́a Buti, José Luís Calleja, John Goulis, Spilios Manolakopoulos, Harry L.A. Janssen, George Papatheodoridis, Jeong‐Hoon Lee

2021Clinical Gastroenterology and Hepatology13 citationsDOIOpen Access PDF

Topics & Concepts

MedicineHepatocellular carcinomaInternal medicineGastroenterologyHBeAgHazard ratioCirrhosisCohortEntecavirProportional hazards modelConfidence intervalHepatitis B virusHBsAgImmunologyLamivudineVirusHepatitis B Virus StudiesHepatitis C virus researchHepatocellular Carcinoma Treatment and Prognosis